Loading…
DIA Europe 2019 has ended
Back To Schedule
Tuesday, February 5 • 16:00 - 17:30
#EF01: Executive Forum (Invitation Only): Europe’s Readiness to Face the Requirements of Future Therapies

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Component Type: Session

Effective therapies are coming fast and furious, often with higher and higher pricing. While effective treatments increase efficiency and reduce treatment costs, there are no processes nor mechanisms that exist in Europe to claw back funding from regional budgets that create savings locally. What needs to change, if anything? What evidence and systems need to be developed to fix this problem, or is it not a problem at all? This session will discuss: • The market for Orphan indications is growing 11% per year, and will be 25% of drug spending by the year 2025. Is this a good or a bad thing? • Playing Hot Potato with Pricing - How do we build a reimbursement system fit for purpose?

Chair

Duane Schulthess, MBA

Speaker

Panelist
Alexander Natz, JD

Panelist
Bettina Ryll

Panel Discussion
Tomas Salmonson, PhD

Panelist
Anja Schiel, PhD


Speakers
AN

Alexander Natz

Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Dr. Natz is Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org). From 2008-2013 he has been heading the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he has been a lawyer with Sträter Law Firm in Germany... Read More →
avatar for Bettina Ryll

Bettina Ryll

Chair ESMO Patient Advocates Working Group (PAWG), Melanoma Patients
Bettina Ryll, MD/PhD founded the Melanoma Patient Network Europe in 2013 and developed a special interest in patient-centric clinical research and drug development. Bettina’s current areas of focus are Adaptive Licensing/ MAPPS , innovative sustainable healthcare models and patient-centered... Read More →
avatar for Anja Schiel

Anja Schiel

Special Advisor, Lead Methodologist; Leader international HTA (iHTA) NoMA, Norwegian Medicines Agency (NoMA), Norway
Anja Schiel has studied Biology at the Johannes Gutenberg-University, Mainz, Germany. She received her PhD from the Free University in Amsterdam in 2006 and worked several years as Post-Doc before starting at the Norwegian Medicines Agency (NoMA) in 2012. At NoMA she is working as... Read More →
avatar for Duane Schulthess

Duane Schulthess

Chief Executive Officer, Vital Transformation LLC, United States
Duane is the Managing Director of Vital Transformation which consults to national health authorities, blue chip multi-national organisations, governments, and stakeholder groups on healthcare policy and technology. He and his firm have developed many unique techniques and methods... Read More →
avatar for Tomas Salmonson

Tomas Salmonson

Senior Scientific Advisor, Medical Products Agency (MPA)
Tomas Salmonson, M.Sc., PhD, brings outstanding experience and expertise from a long career in the regulation of medicines both on a national and European level to his new role. A pharmacist by training, he is currently senior scientific advisor at the Swedish Medical Products Agency... Read More →

Tuesday February 5, 2019 16:00 - 17:30 CET
0.94-0.95 (Level 0) Austria Center Vienna Bruno-Kreisky-Platz 1 1220 Vienna Austria
  Executive Forum, Session